Document:

<PAGE>

                                                                   Exhibit 10.54

                          AMENDMENT TO CREDIT AGREEMENT

     THIS AMENDMENT TO CREDIT AGREEMENT (this "AMENDMENT") is effective as of
February 27, 2007 by and among THE BOSTON BEER COMPANY, INC. and BOSTON BEER
CORPORATION (together, the "Borrowers" and each individually, a "Borrower"); and
BANK OF AMERICA, N.A., a national banking association, successor-by-merger to
Fleet National Bank (the "Bank").

                                    RECITALS

     A. The Bank and the Borrowers are parties to that certain Second Amended
and Restated Credit Agreement dated as of July 1, 2002, as modified by a letter
agreement dated August 4, 2004 and as further modified by letter agreement dated
as of December 30, 2005 (as modified, the "Credit Agreement"). Capitalized terms
used herein without definition have the meanings assigned to them in the Credit
Agreement.

     B. The Borrowers have requested that the Bank extend the Expiration Date.

     C. The Bank is willing to make such amendment, subject to the terms and
conditions set forth herein.

     NOW, THEREFORE, in consideration of the premises and the mutual agreements
herein contained, the parties hereto hereby agree as follows:

I.   AMENDMENT TO CREDIT AGREEMENT.

     A. Extension of Expiration Date. SECTION 1.1 of the Credit Agreement is
amended so that the "Expiration Date", as defined therein, shall be March 31,
2008.

     B. Further Amendments. Except as specifically amended above, the text of
the Credit Agreement shall remain unmodified and in full force and effect and is
hereby ratified and affirmed in all respects.

II.  MISCELLANEOUS.

     A. The Borrowers hereby represent and warrant that (a) all of the
Borrowers' representations and warranties contained in Section 3 of the Credit
Agreement are true and correct in all material respects as of the date hereof
(except for representations and warranties made as of a specified date, which
shall be true and correct as of such date) and (b) no Default has occurred and
is continuing.

     B. This Amendment shall be governed by and construed in accordance with the
internal laws of the Commonwealth of Massachusetts.

     C. This Amendment may be executed by the parties hereto in several
counterparts hereof and by the different parties hereto on separate counterparts
hereof, all of which counterparts shall together constitute one and the same
agreement. Delivery of an executed

<PAGE>

signature page of this Amendment by facsimile transmission shall be effective as
an in-hand delivery of an original executed counterpart hereof.

     IN WITNESS WHEREOF, the parties have caused this Amendment to be executed
under seal by their duly authorized officers under seal as of the day and year
first above written.

                                        THE BOSTON BEER COMPANY, INC.

                                        By: /s/ William F. Urich
                                            ------------------------------------
                                        Name: William F. Urich
                                        Title: CFO

                                        BOSTON BEER CORPORATION

                                        By: /s/ William F. Urich
                                            ------------------------------------
                                        Name: William F. Urich
                                        Title: CFO

                                        BANK OF AMERICA, N.A.

                                        By: /s/ Luanne T. Smith
                                            ------------------------------------
                                        Name: Luanne T. Smith
                                        Title: Vice President

                                       -2-exv10w29

 

Exhibit 10.29

SETTLEMENT TERM SHEET AGREEMENT

     This agreement, dated September 29, 2006, is between Ethypharm S.A. France and Ethypharm S.A.
Spain (individually and collectively, “Ethypharm”) and Bentley Pharmaceuticals, Inc. (“Bentley”)
and Laboratorios Belmac S.A. (“Belmac”). Ethypharm, Bentley and Belmac (collectively, “the
Parties”) have reached a settlement of their dispute. The Parties intend to reduce the terms of
the settlement to a written agreement for execution within the next thirty days, following approval
of their respective boards of directors. In advance of preparing the Settlement Agreement, the
parties have signed this term sheet, fully intending this to be a legally binding document. The
principal terms of the Parties’ agreement are as follows:

	 	1.	 	Ethypharm will cause the lawsuit captioned Ethypharm S.A. France and
Ethypharm S.A. Spain v. Bentley Pharmaceuticals, Inc., United States District Court
for the District of Delaware, Civil Action No. 04-1300-SLR (the “Delaware Action”)
to be dismissed with prejudice, with all parties paying their own costs and
attorneys’ fees and waiving all rights of appeal.
	 
	 	2.	 	Ethypharm will cause the patent litigation that it has filed against
Belmac in Spain, Ethypharm S.A. v. Laboratorios Belmac, S.A., Juzgado de lo
Mercantil N° 5, Procedimiento Ordinario 170 / 2005, filed on April 20, 2005 (the
“Spanish Action”) to be dismissed with prejudice, with all parties paying their own
costs and attorneys’ fees and waiving all rights of appeal.
	 
	 	3.	 	The Parties will release each other from any all claims and
counterclaims that were brought or could have been brought in the Delaware Action
or in the Spanish Action, including without limitation claims of misappropriation
of trade secrets, interference with customer or advantageous commercial relations
and

 

 

	 	 	 	patent infringement, and will release each other from all claims and demands of any
description that they have now or may have against each other concerning or arising out
of the facts or claims concerning omeprazole, either in its organic or aqueous
formulations, lansoprazole or other pellet drugs arising out of the facts or claims
asserted in the Delaware Action or the Spanish Action. The parties will further
release each other from all other claims and demands that they have or may have against
each other, through and including the execution date of the Settlement Agreement. 
	 
	 	4.	 	Belmac will pay Ethypharm as follows:
	 
	 	 	 	$ 4 million upon execution of the Settlement Agreement; and
	 
	 	 	 	$ 4 million paid in equal installments over the next four years.
	 
	 	 	 	Bentley will guarantee all such payments.
	 
	 	5.	 	The Parties agree that terms of this settlement will be confidential
except as may be required by law, necessary to effect the terms of the settlement,
or otherwise necessary for the internal business communications of the Parties.
	 
	 	6.	 	Nothing in the settlement will constitute an admission of any kind or
an acknowledgment of liability, including the issue of agency.
	 
	 	7.	 	The Parties will return or certify the destruction of each other’s
Confidential or Highly Confidential documents that were produced, with the
exception of any court pleadings or appendices thereto, as provided in the
Stipulated Protective Order.
	 
	 	8.	 	The Parties acknowledge that board approval of these terms is required,
which approval shall be obtained by October 6, 2006.

 

 

	 	 	 
	ETHYPHARM S.A. FRANCE and

	 	BENTLEY PHARMACEUTICALS, INC.
	ETHYPHARM S.A. SPAIN
	 	 

	 	 	 
	By:

	 	By:
	 
	 	 
	/s/ Gérard M. LeDuc

	 	/s/ James Murphy
	 

	 	 
	Gérard M. LeDuc, Président & CEO

	 	James Murphy, Chairman and CEO
	Ethypharm, SA France

	 	Bentley Pharmaceuticals, Inc.
	194, Bureaux de la Colline

	 	2 Holland Way
	Bâtiment D – 92213 Saint-Cloud Cedex

	 	Exeter, New Hampshire 03833
	France

	 	USA
	 
	 	 
	Gérard M. LeDuc, Presidente
	 	 
	Ethypharm, S.A Madrid Spain
	 	 

LABORATORIOS BELMAC, S.A.

	 	 	 
	By:
	 	 
	 
	 	 
	/s/ Adolfo Herrera
 

	 	 
	Adolfo Herrera, Director General
	 	 
	Laboratorios Belmac, S, A
	 	 
	Calle Teide, n. 4 planta baja
	 	 
	Parque Empressarial “La Marina”
	 	 
	28700 San Sebastian de los Reyes, MADRID
	 	 

Dated: September 29, 2006<PAGE>

                        AMENDMENT TO EMPLOYMENT AGREEMENT

     This Amendment to Employment Agreement ("Amendment"), dated as of January
12, 2007, is entered into by and between Lightbridge, Inc., a Delaware
corporation (the "Company") and Robert E. Donahue of Northborough, Massachusetts
(the "Executive").

     WHEREAS, the Company and the Executive are parties to that certain
Employment Agreement, dated as of January 7, 2005 (the "Employment Agreement");

     WHEREAS, in accordance with Section 13(a) of the Employment Agreement, the
Company and the Executive wish to amend Sections 3(e) and 3(f) of the Employment
Agreement;

     NOW THEREFORE, in consideration of the mutual promises herein contained and
for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Company and the Executive hereby agree as follows:

     1.   The first sentence of Section 3(e) of the Employment Agreement is
hereby deleted in its entirety and the following substituted in its place and
stead:

          The other Stock Option (the "Second Stock Option") shall be for
          150,000 shares of Common Stock and such shares shall vest as follows:
          (i) in the event that the average closing price of Common Stock (as
          reported by the Nasdaq National Market) over any 20 consecutive
          trading day period beginning on or after the Effective Date and ending
          on or before the date the Executive's employment under this Agreement
          as President and Chief Executive Officer terminates (the "Average
          Closing Price") equals or exceeds $12.50, such Stock Option shall
          immediately vest as to 50,000 of such shares; (ii) in the event that
          the Average Closing Price during such period equals or exceeds $15.00,
          such Stock Option shall immediately vest as to an additional 50,000 of
          such shares; and (iii) in the event that the Average Closing Price
          during such period equals or exceeds $17.50, the Stock Option shall
          immediately vest in full.

     2.   The first sentence of Section 3(f) of the Employment Agreement is
hereby deleted in its entirety and the following substituted in its place and
stead:

          In the event that, within two (2) years following a Change of Control,
          either (i) the Company (or its successor) terminates the Executive's
          employment without Cause or (ii) the Executive terminates his
          employment for Good Reason (as defined below), then (A) any
          unexercised Company stock options then held by the Executive shall
          immediately vest in full and shall remain exercisable for 90 days
          following such termination, (B) subject to the Executive's execution
          of the Release and the Severance Agreement and to the provisions of
          Section 14 below, the Company shall pay the Executive in one lump sum
          payment an amount equal to 1.5 times his then-current Annual Base
          Salary plus 1.5 times the bonus earned by the Executive in respect of
          the immediately preceding calendar year (or, if the Company's
          Compensation Committee has not yet made a determination regarding

<PAGE>

          the amount of such bonus, 1.5 times 60% of the Executive's target
          bonus for such year), and (C) the Executive and his family members
          will be eligible to continue his group health insurance coverage in
          accordance with the federal COBRA law.

     3.   Capitalized terms used herein and without definition shall have their
respective meanings as set forth in the Employment Agreement.

     4.   The Company and the Executive hereby ratify and confirm that all of
the covenants, agreements, terms, conditions and other provisions of the
Employment Agreement are in full force and effect and unmodified, except as
altered by this Amendment.

     5.   This Amendment may be executed in one or more counterparts. A
facsimile or copy of a signature is valid as an original.

                                        2
<PAGE>

     IN WITNESS WHEREOF, the Company and the Executive have executed this
Amendment as of the date first written above.

                                           LIGHTBRIDGE, INC.

                                           /s/ Kevin C. Melia
                                           ----------------------------------
                                           Kevin C. Melia
                                           Chairman of the Board of Directors

                                           /s/ Robert E. Donahue
                                           ----------------------------------
                                           Robert E. Donahue

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]